EDSA
Edesa BiotechยทNASDAQ
--
--(--)
--
--(--)
EDSA Profile
Edesa Biotech, Inc.
A clinical-stage biopharmaceutical company that developing drugs for dermatological and anorectal diseases
Biological Technology
09/09/1999
11/05/2015
NASDAQ Stock Exchange
17
09-30
Common stock
100 Spy Court, Markham, ON, Canada L3R 5H6
--
Founded on September 9, 1999, Edesa Biotech, Inc., is a biopharmaceutical company that develops innovative therapies for inflammation and immune-related diseases, with a clinical focus on medical dermatology and respiratory diseases. Its dermatology product line includes EB06, an anti-CXCL10 monoclonal antibody under development for vitiligo, a Phase 2 study approved by Health Canada and in discussions with the U.S. FDA, and EB01 (1.0% daniluromer cream), a Phase 3 ready-to-treat therapy for allergic contact dermatitis. In its respiratory program, EB05 (paridiprubart), a novel stay-oriented therapy, showed statistically significant survival and rehabilitation benefits in a Phase 3 trial of Acute Respiratory Distress Syndrome (ARDS) and continues to be studied under a U.S. government-funded platform. The Canadian government is also supporting development costs through grant funding, and the company is seeking to increase the use of paridiprubart in chronic diseases.
